[quick news] the first class of new drugs jointly developed by Treasure Island pharmaceutical and Wuxi apptec were accepted, and Haizheng subsidiary received 3.85 million government subsidies

On September 4, Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd announced that its subsidiary Harbin Zhenbao Pharmaceutical Co., Ltd (hereinafter referred to as "Harbin Zhenbao") had recently obtained the acceptance notice of hzb1006 API and its capsules issued by the State Drug Administration The specific situation is as follows: the main content of the acceptance notice is drug research and development The drug is a class 1 innovative drug jointly researched and developed by HA Zhenbao and Shanghai yaomingkant new drug development Co., Ltd according to the "technical development contract for class 1 new drug project of Pan FGFR inhibitor treatment for liver cancer" signed by both parties Ha Zhenbao owns independent intellectual property rights Fibroblast growth factor receptor (FGFR) plays an important role in cancer The activation mutation or amplification of FGFR in cells can lead to the over activation of FGF-FGFR signal pathway, which leads to the over proliferation, escape from apoptosis, easy migration and other carcinogenic characteristics of cells Vascular endothelial growth factor (VEGF) is closely related to angiogenesis and angiogenesis, and it is a proven target of antitumor drugs The combination of VEGF blocker and FGFR blocker can make up for the drug resistance when they are used alone Hzb1006 capsule is a multi kinase inhibitor mainly composed of FGFR and VEGFR It has dual effects of cell inhibition and anti angiogenesis The mechanism of action of the drug is clear, and the target selectivity of efficacy is high It is evaluated in preclinical liver cancer model, showing that the in vivo efficacy is better than that of the same listed control drug, with better safety, drug-forming and clinical development value According to the relevant national registration laws and regulations, the drug has been accepted for registration, and will be reviewed by the drug review center of the State Drug Administration After the review, the clinical work will be carried out Up to now, the accumulated R & D investment of the project is about 26 million yuan, and the follow-up Zhendao pharmaceutical industry will further increase the product R & D investment About the same kind of drugs The target drug has been listed: toluenesulfonic acid sorafenib produced by Bayer, Germany According to the announcement information, the domestic sales in 2017 was 779.51 million yuan The variety under study is erdafitinib of Janssen biotechnology Inc., a subsidiary of Johnson & Johnson, and the phase II clinical research is under way Haizheng subsidiary received 3.58 million subsidies from the government for major special projects On September 4, Zhejiang Haizheng Pharmaceutical Co., Ltd announced that its holding subsidiary Haizheng Pharmaceutical (Hangzhou) Co., Ltd (hereinafter referred to as "Haizheng Hangzhou company") has participated in the national science and technology major special project led by Tianjin Pharmaceutical Group Co., Ltd "Research on major common key technologies for new inhalation drug delivery preparations and their large-scale development" Recently, Haizheng Hangzhou Co., Ltd received 3.588 million yuan of central financial funds transferred from Tianjin Pharmaceutical Group Co., Ltd., which was specifically used for the sub topic "Research on common key technologies for large-scale development of new inhalation preparations" Information source: Announcement statement of Listed Enterprises: the viewpoint of this article only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.